NovaXS Biotech
Early Stage
Needle-free self-injection technology | Ease of use, painless, better care
Overview
Raised: $109,198
Total Commitments ($USD)
Platform
Republic
Start Date
12/06/2022
Close Date
02/03/2023
Min. Goal
$25,000
Max. Goal
$1,235,000
Min. Investment
$100
Security Type
SAFE
Series
Seed
Funding Type
RegCF
Valuation Cap
$14,000,000
Discount Rate
20%
Rolling Commitments ($USD)
Status
Active
Reporting Date
02/03/2023
Days Remaining
0
% of Min. Goal
437%
% of Max. Goal
9%
Likelihood of Max
Avg. Daily Raise
$1,851
# of Investors
212
Momentum
Create a free account today to gain access to KingsCrowd analytics.
Location
Trabuco Canyon, California
Industry
Healthcare & Pharmaceuticals
Tech Sector
Biotech
Distribution Model
B2B
Margin
Medium
Capital Intensity
Low
NovaXS Biotech, with a valuation of $14 million, is raising funds on Republic. The company is developing needle-free self-injection technology for ease of use, painless drug delivery, and better care. NovaXS Biotech smart system aims to simplify the medication self-administration process and improve remote treatment outcomes with one simple click on the device. NovaXS Biotech has filed four patents to protect its technology, is finalizing prototypes, and targeting commercial launch in the second quarter of 2024. Alina Su, Jonathan Xing, and Alex You founded NovaXS Biotech in January 2021. The current crowdfunding campaign has a minimum target of $25,000 and a maximum target of $1.24 million. The campaign proceeds will be used to initiate licensing, launch the product, and promote sales.
Summary Profit and Loss Statement
| Most Recent Year | Prior Year | |
|---|---|---|
|
Revenue |
$0 |
$0 |
|
COGS |
$0 |
$0 |
|
Tax |
$0 |
$0 |
| ||
| ||
|
Net Income |
$-62,494 |
$0 |
Summary Balance Sheet
| Most Recent Year | Prior Year | |
|---|---|---|
|
Cash |
$297,216 |
$0 |
|
Accounts Receivable |
$0 |
$0 |
|
Total Assets |
$297,216 |
$0 |
|
Short-Term Debt |
$7,872 |
$0 |
|
Long-Term Debt |
$290,000 |
$0 |
|
Total Liabilities |
$297,872 |
$0 |
Financials as of: 12/06/2022
Create a free account today to gain access to KingsCrowd analytics.
Upgrade to gain access
Pay Monthly
Annually (Save 17%)
-
$12.42 /month
billed annually - Free portfolio tracking and KingsCrowd's quantitative ratings on all raises.
- Plan Includes:
- Everything in Free, plus
- Company specific
KingsCrowd ratings (excluding risk)
- Advanced company search ( with ratings)
- Markets page filters and historical industry data
- Get Edge Annual
Edge
-
$41.58 /month
billed annually - Full site access including KingsCrowd's qualitative analyst reports.
- Plan Includes:
- Everything in Edge, plus
- Full access to detailed Analyst Reports (e.g. Top Deal, Deal to Watch, Neutral, and Underweight)
- Search and filter based on Analyst Reports
- In-depth risk ratings for every raise
- Get Edge Pro Annual
Edge Pro
Already a member? Log in here.
Ratings 
